Cetrotide Shortage: What Providers and Prescribers Need to Know in 2026

Provider Briefing: Cetrotide (Cetrorelix Acetate) Availability in 2026

For reproductive endocrinologists, OB/GYNs, and fertility clinic staff, medication access challenges aren't new. But when patients call your office saying they can't find Cetrotide — often mid-stimulation cycle — it creates a clinical urgency that requires a clear, current understanding of the supply landscape.

This briefing covers the current status of Cetrotide (Cetrorelix Acetate), the generic competitive landscape, prescribing implications, cost considerations, and tools to help your patients find medication in stock.

Current Shortage Status and Timeline

As of early 2026, Cetrotide is not listed on the FDA or ASHP drug shortage databases. There is no formally recognized shortage of Cetrorelix Acetate.

However, practical availability at the pharmacy counter doesn't always reflect database status. Clinicians should be aware of the following dynamics:

• 2000: FDA approval of Cetrotide (EMD Serono) in 0.25 mg and 3 mg formulations
• 2022: First generic Cetrorelix Acetate approved (Teva, via Competitive Generic Therapy designation)
• 2024: Three additional generics approved (Qilu, Livzon, Gland — all April 2024)
• 2025: Fifth generic approved (Xiromed, June 2025)
• Discontinued: The 3 mg single-dose formulation of brand-name Cetrotide is no longer manufactured

The discontinuation of the 3 mg formulation has shifted all patients to the 0.25 mg daily dose, effectively increasing unit demand by 5-7x per patient cycle.

Prescribing Implications

Generic Substitution

With five FDA-approved generic manufacturers now in the market, generic Cetrorelix Acetate should be the first-line prescribing approach for most patients. The generics are bioequivalent and significantly less expensive.

Key considerations:

• Prescribe generically: Writing for "Cetrorelix Acetate" rather than "Cetrotide" allows pharmacies maximum flexibility in sourcing
• Avoid DAW (Dispense as Written): Unless there is a documented clinical reason, brand-only prescriptions limit pharmacy options and may trigger prior authorization delays
• Insurers increasingly require generic first: Cigna and other major payers now require trial of generic Cetrorelix before approving brand-name Cetrotide

Therapeutic Interchange: Ganirelix

If no Cetrorelix formulation (brand or generic) is available, Ganirelix remains a clinically interchangeable GnRH antagonist:

• Same mechanism of action
• Same dose: 0.25 mg SC daily
• Equivalent clinical outcomes per ESHRE guidelines (pregnancy rates, oocyte yield, live birth rates)
• Pre-filled syringe format (no reconstitution required)
• May actually improve patient compliance and reduce preparation errors

Mid-cycle substitution from Cetrorelix to Ganirelix is generally feasible without protocol modification, though documentation of the clinical rationale is recommended.

The Availability Picture

Cetrotide and Cetrorelix availability is shaped by the specialty pharmacy distribution model:

• Retail chains: CVS, Walgreens, and Rite Aid do not routinely stock fertility injectables. Patient attempts to fill at these locations will frequently result in "not in stock" responses.
• Specialty pharmacies: Freedom Fertility, Encompass, Village Fertility, Alto, and clinic-affiliated pharmacies are the primary distribution channel
• Wholesaler variability: Not all pharmacies have access to all five generic manufacturers. Smaller specialty pharmacies may carry only one or two options.

Encouraging patients to use specialty pharmacies — and providing specific pharmacy referrals from your clinic — remains the most effective strategy for avoiding access gaps.

Cost and Access Considerations

Cost is a significant barrier for fertility patients, particularly those without insurance coverage for IVF medications:

Current Pricing Landscape

• Brand Cetrotide (7 kits, 0.25 mg): ~$3,000 retail; ~$377 with GoodRx coupon
• Generic Cetrorelix (7 kits, 0.25 mg): ~$1,630 retail; ~$302-$543 with discount programs
• Single generic vial: From approximately $63

Patient Assistance Programs

• EMD Serono Fertility Instant Savings Program: Immediate savings card for eligible patients on brand-name Cetrotide, Gonal-f, and Ovidrel
• Compassionate Care Program: Income-based assistance providing 50-75% off self-pay pricing for eligible patients
• Fertility LifeLines (1-866-LETS-TRY): EMD Serono's support line for insurance navigation, copay assistance, and pharmacy referrals
• Replacement Drug Program: Covers replacement medication for cycles cancelled due to unforeseen circumstances

Clinic financial counselors should be aware of these programs and proactively connect patients, particularly self-pay and underinsured patients.

Tools and Resources for Your Practice

Medfinder for Providers

Medfinder for Providers allows clinical staff to search for pharmacy-level stock availability of Cetrotide and Cetrorelix in real time. This can be integrated into your clinic's workflow when patients report access difficulties.

Rather than asking patients to make multiple phone calls, your team can identify stocked pharmacies and direct patients accordingly — reducing cycle disruptions and patient anxiety.

Patient-Facing Resources

Consider sharing these resources with patients experiencing difficulty finding Cetrotide:

• Why is Cetrotide so hard to find?
• How to find Cetrotide in stock near you
• Alternatives to Cetrotide
• How to save money on Cetrotide

Looking Ahead

The generic Cetrorelix market is maturing rapidly. With five approved manufacturers and increasing competition, availability should continue to improve and prices should continue to decline through 2026 and beyond.

Key trends to watch:

• Oral GnRH antagonists: Relugolix (Orgovyx) and other oral formulations are being explored in reproductive medicine contexts, which could eventually reduce reliance on injectable GnRH antagonists
• Specialty pharmacy expansion: More specialty pharmacies are entering the fertility medication space, improving geographic coverage
• Insurer mandates: States continue to expand fertility coverage mandates, which increases both demand and formulary coverage for GnRH antagonists

Final Thoughts

While Cetrotide is not in a formal shortage, the practical challenges of specialty medication distribution mean providers must remain proactive. Prescribe generically when possible, maintain partnerships with reliable specialty pharmacies, educate patients about generic options, and use tools like Medfinder for Providers to streamline medication access.

For related provider resources, see our guide on how to help your patients find Cetrotide in stock and our provider's guide to helping patients save money on Cetrotide.